Preclinical optimisation and evaluation of controlled release ophthalmic depots for anti-VEGF treatments: readiness for Pharma partnering

用于抗 VEGF 治疗的控释眼科长效制剂的临床前优化和评估：为制药合作做好准备

• 批准号: 10027309
• 金额: $ 82.48万
• 依托单位: NANOPTIMA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10027309
• 关键词: Preclinical; optimisation; evaluation; controlled; release

**NanOptima has a mission to reduce the colossal burden of treatment for retinal diseases, specifically "wet" age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion**. These conditions are estimated to affect 570,000 people in the UK and and at least 96M worldwide. Current proven protein drug treatments preserve sight, but require intravitreal injections every 1-2 months, which is costly for healthcare systems since injections must be done by trained clinicians, is very unpleasant for patients, and loses days of patients' and carers' time, while every injection carries a low but accumulating risk of serious complications.Worrying public reaction to COVID-19 has resulted in a dramatic trend of patients neglecting signs of vision loss and not presenting to a perceived high-risk environment such as a hospital (incidence down nearly 80% from 2019). As COVID-19 risk decreases, there will likely be a considerable surge in the presentation of emergency cases with more advanced sight loss, to an already overburdened healthcare system (_Eye_ volume 34, pages 1189--1192(2020)).NanOptima is designing nano-scale drug-release depots constructed from self-assembling polymer filaments and natural human biopolymers. The materials we use will break down into compounds that occur normally throughout the human body. The depots are designed to be injected infrequently, through a very fine needle with no need for surgical implantation, delivering proven existing retinal treatments with the intention of being formulated in future with novel treatments under development in the pharmaceutical industry. The solution will make treatment less invasive, reduce risks, distress and costs, and maintain sight-protecting treatment levels for longer.NanOptima is a small UK company based at Alderley Science Park where we have access to high-tech equipment and facilities, and are supported by an unrivalled pool of experienced pharmaceutical specialists. In this project, NanOptima will partner closely with a leading academic materials design group at the **University of Manchester**, with a track record of translating research into clinical and commercial sector.On successful completion of this project, NanOptima expects to partner internationally with ophthalmic pharmaceutical companies, sharing risk and attracting inward investment into the UK. Our company intends to grow and create new science jobs in advanced healthcare technology and in delivering our projects, we will also create work for UK contract research organisations. Ultimately, we expect the products to benefit patients worldwide, reduce healthcare costs, and generate revenue for UK businesses.

**NanOptima的使命是减轻视网膜疾病的巨大治疗负担，特别是“湿性”年龄相关性黄斑变性、糖尿病视网膜病变和视网膜静脉阻塞 **。据估计，这些疾病影响了英国57万人，全球至少9600万人。目前已被证实的蛋白质药物治疗保留了视力，但需要每1-2个月进行一次玻璃体内注射，这对于医疗保健系统来说是昂贵的，因为注射必须由受过训练的临床医生完成，这对患者来说是非常不愉快的，并且浪费了患者和护理人员数天的时间，而每一次注射都有很低但不断累积的严重并发症风险。令人担忧的公众对COVID-19的反应-19导致患者忽视视力丧失的迹象，并且没有出现在医院等高风险环境中（发病率比2019年下降近80%）。随着COVID-19风险的降低，对于已经负担过重的医疗保健系统来说，更严重的视力丧失的紧急病例可能会大幅增加（_Eye_ volume 34，pages 1189- 1192（2020））NanOptima正在设计由自组装聚合物长丝和天然人类生物聚合物构建的纳米级药物释放仓库。我们使用的材料将分解成通常在人体内发生的化合物。这些储库被设计为不经常注射，通过非常细的针头，无需手术植入，提供经过验证的现有视网膜治疗，旨在未来与制药行业正在开发的新型治疗一起配制。NanOptima是一家位于英国阿尔德利科技园的小型公司，在这里我们可以使用高科技设备和设施，并得到经验丰富的制药专家的支持。在这个项目中，NanOptima将与 ** 曼彻斯特大学 ** 的一个领先的学术材料设计小组密切合作，该小组在将研究转化为临床和商业领域方面有着良好的记录。在这个项目成功完成后，NanOptima希望与眼科制药公司进行国际合作，分担风险并吸引外国投资进入英国。我们公司打算在先进的医疗保健技术和交付我们的项目方面发展和创造新的科学工作，我们还将为英国合同研究组织创造工作。最终，我们希望这些产品能够造福全球患者，降低医疗成本，并为英国企业创造收入。